Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the MHRA press release on Evusheld approved to prevent covid-19 in people whose immune response is poor, published on 17 March 2022, whether the NHS (a) has made and (b) plans to make an assessment of the potential merits of trialling Evusheld in real-world evidence studies prior to its potential full rollout.

The National Health Service and experts are evaluating all available evidence to inform decisions on Evusheld, including whether real world evaluation could improve our understanding of efficacy against new variants. In addition, the Antivirals and Therapeutics Taskforce is engaging with countries using Evusheld to understand any plans for assessing real world evidence as it becomes available.